health
We want to boost Colombia as a platform for introducing new technologies: Galderma
Mauricio de Oliveira, general manager of Galderma Colombia Photo: Courtesy Galderma
TL;DR
- Colombia is a strategic market for Galderma in Latin America due to its accelerated growth, innovation, medical tourism, and access to dermatological treatments.
- Galderma is experiencing strong double-digit growth globally and in Colombia, operating across three segments: injectable aesthetics, therapeutic dermatology, and dermatological skin care.
- Key growth drivers include the injectable aesthetics segment, particularly with the biostimulator Sculptra, and therapeutic dermatology for conditions like acne.
- Colombian consumers are increasingly seeking preventative aesthetic treatments, natural results, and improved skin quality (texture, luminosity, elasticity), with a trend towards personalized treatment plans.
- Galderma invests in medical education, training over 10,000 professionals globally annually, with Colombia having a technically sophisticated medical community.
- Colombia is a significant medical tourism destination, attracting foreign patients for both general preventative care and aesthetic medicine.
- The company notes a trend towards holistic well-being in dermatology, integrating healthy habits and medical solutions, with a focus on the skin microbiome and managing sensitive skin with brands like Cetaphil.
- The increasing prevalence of acne and its psychological impact are also key areas of focus for Galderma.
- Injectable aesthetics constitute the largest segment of Galderma's sales in Colombia (40%), driven by local demand for beauty and care.
- Colombia's institutional channel provides significant access to acne treatments through its public health system, benefiting a large number of patients.
- Galderma views Colombia as an acceleration market in Latin America, capitalizing on aesthetic trends, medical tourism, and the public/private access for therapeutic dermatology.
- Despite challenges in Colombia's healthcare system, such as financing crises, Galderma sees the institutional market as mature and aims to ensure continuous patient access to treatments.
- Recent innovations introduced by Galderma in Colombia include Alastin for post-aesthetic procedure recovery, a new Cetaphil serum, and Benzac Parches for acne treatment.
- Galderma is positioning Colombia as a platform for introducing new global technologies and therapies rapidly, despite regulatory delays.
- The company has increased its Colombian workforce threefold in four years and sees the country as a base for operations in regions without affiliated entities.
- Colombia's competitiveness in tax, logistics, and bureaucracy, along with its skilled talent and geographical location, makes it attractive for investment.
- Dermatology is globally recognized as a high-growth segment, projected at 7% for the next five years, with Galderma being a 100% dermatology-focused Swiss company with over $5 billion in global revenue.